BEACOPP

BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group used for patients in Stages > II or early with unfavorable risk factors.
Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21.
There also exists a more intensive regimen with cycles of 14 days. Usually a course of BEACOPP therapy consists of four, sometimes six to eight cycles, or in combination with ABVD.
In some countries BEACOPP still is experimental, in others it is a standard therapy. In the United States, ABVD is generally given instead, because of the possibility of BEACOPP inducing more secondary neoplasias, although the final results from a clinical trial indicate that "there were no overall differences in treatment-related mortality or secondary malignancies" of BEACOPP relative to ABVD.
Some believe that the BEACOPP regimen is used less often in the US for cost reasons:

Twice as many infusion per cycle relative to ABVD;
Requirement for G-CSF support, which was under patent protection in the US until 2013, while that patent protection expired in the EU in 2008;
Higher likelihood of adverse events requiring hospitalization, such as infection or acute toxicity;

However, BEACOPP delivers approximately 7% points success relative to ABVD for early unfavorable Hodgkin lymphoma and 12% points greater success relative to ABVD for advanced Hodgkin lymphoma as measured by seven-year freedom from treatment failure.
Predecessors of BEACOPP were COPP and MOPP.

Dosing regimen

Drug	Base BEACOPP	Dose-Escalated BEACOPP	Method	Cycle Day
'leomycin	10 mg/m²	10 mg/m²	i.v. push	day 8
'toposide	100 mg/m²	200 mg/m²	i.v. infusion	day 1–3
'driamycin	25 mg/m²	35 mg/m²	i.v. push	day 1
'yclophosphamide	650 mg/m²	1250 mg/m²	i.v. infusion	day 1
'ncovin=Vincristine	1.4 mg/m²	1.4 mg/m²	i.v. infusion	day 8
'rocarbazine	100 mg/m²	100 mg/m²	orally	day 1–7
rednisone	40 mg/m²	40 mg/m²	orally	day 1–14